Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173

NCT02217839 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: DG3173
DRUG: DG3173+Octreotide
DRUG: Octreotide
DRUG: DG3173 Placebo
DRUG: DG3173 Placebo+Octreotide Placebo
DRUG: Octreotide+DG3173 Placebo

Sponsor

Aspireo Pharmaceuticals Limited